Valid concern! From the Ann: Investor Webinar Presentation on the 17/11/21 they stated:
Mind you this includes both the FIH trial for Alzheimer's and the FIP trial for Glaucoma. It would be very disappointing should a CR be required before either of these outcomes. $3m spend in the last quarter on pre-clinical activities seems high, lets hope some of this is upfront expenditure for the trials
Valid concern! From the Ann: Investor Webinar Presentation on...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.639M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 130814 | 3.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 25184 | 2 |
View Market Depth
| Last trade - 10.25am 03/07/2024 (20 minute delay) ? |
| NSB (ASX) Chart |
Day chart unavailable